Royce & Associates LP Takes $339,000 Position in Progyny, Inc. (NASDAQ:PGNY)

Royce & Associates LP purchased a new position in Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,639 shares of the company's stock, valued at approximately $339,000.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after purchasing an additional 1,246 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares during the last quarter. Caitlin John LLC grew its position in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after buying an additional 3,183 shares during the period. SBI Securities Co. Ltd. purchased a new stake in Progyny during the fourth quarter valued at approximately $74,000. Finally, KBC Group NV raised its position in Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after acquiring an additional 2,140 shares during the period. Institutional investors own 94.93% of the company's stock.

Insider Transactions at Progyny

In other news, Chairman David J. Schlanger acquired 150,000 shares of the business's stock in a transaction dated Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.30% of the company's stock.

Remove Ads

Progyny Trading Up 1.6 %

PGNY traded up $0.35 on Wednesday, hitting $21.84. 1,196,210 shares of the company's stock traded hands, compared to its average volume of 1,614,410. The company's 50 day simple moving average is $21.99 and its 200-day simple moving average is $18.53. Progyny, Inc. has a one year low of $13.39 and a one year high of $38.98. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of 37.66, a P/E/G ratio of 2.39 and a beta of 1.41.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group boosted their price target on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. Finally, Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Progyny has a consensus rating of "Hold" and an average price target of $24.82.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.